Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Friday, December 8, 2017

Investorideas.com - Investor Ideas Adds to #AI, #Tech, #Biotech & #Mining #stock Directories

Investorideas.com - Investor Ideas Adds to #AI, #Tech, #Biotech & #Mining #stock Directories



Both companies cross-over
into the biotech/life sciences stock list.



The other new biotech company is also Canadian
Listed - NanoSphere Health Sciences Inc. (CSE:NSHS) which is
specializing in the creation of a NanoSphere Delivery System™ (NDS) for the
supplement, nutraceutical, over-the-counter pharmaceutical industries, and
beyond.

Wednesday, December 6, 2017

More Stocks added than ever before- Last month to join at current prices

Investor Ideas New Membership Price as More Stocks added than ever before!

Last month to join at current prices  

Investorideas continues to help its members make smart trading decisions by providing trading news, ideas and access to stock directories in the hottest sectors- bitcoin and blockchain, cannabis, IoT, AI, mining, biotech and more… 


Bitcoin / Blockchain

Cannabis / Hemp

AI/Robotics, Drone Stocks, Internet of Things


We thought you should know Investorideas Membership pricing will change from $49 to $99/year beginning in January 2018. We are tracking more stocks and adding more new stocks to our directory than ever before so we need to increase our prices in the New Year.

Find out more about our membership and why you should join us :

Current members will continue to receive all the benefits of membership until their expiry date, at which time we will send you a reminder notice that it’s time to renew! Renewals will also be $99/year- so you can renew early at these prices too. Just send us an email letting us know and we can get you renewed ahead of schedule at $49.

We spend a lot of hours doing this work for you so you can start trading in your favorite sector. Why do we do it? Because we love these sectors too and love finding the next big idea!

If you are a small retail investor on the hunt for stocks in the sector(s) you like; we help you get started with our stock directories of hundreds of stocks listed in each sector from small to large cap - TSX, TSX.V, CSE, OTC. NYSE. NASDAQ, ASX and more...
*Plus as a member you get our updates each week (posted and emailed each Friday) as we find new stocks in each sector.



What do members get?
  • 24/7 login to all stock directories listed below
  • Monthly updates with new stocks added
  • Weekly News alerts of new stock additions in each sector
  • Sector updates and overview with analyst commentary
  • Podcast alerts
  • Coming soon ICO's and crowdfunding

See a preview of each stock directory - and once you become a member and login you get the entire list!
*Marijuana / Hemp Stocks Directory
(approx. 250 stocks)
*Tech Stocks Directory - features AI and Robotics, Drone Stocks, GPS, Internet of Things (IoT)
*Water Stocks Directory
(over 330 stocks)
*Fuel Cell Stocks Directory
(over 60 stocks)
*Natural Gas Stocks Directory
(over 240 stocks)
*Oil and Gas Stocks Directory
(over 580 stocks)
*China Stocks Directory
(over 325 stocks)
*Biotech Stocks Directory
(over 880 stocks)
*Defense Stocks Directory
(over 680 stocks)

Sign up with Paypal and assign yourself a password. If you forget, we will assign you one. You will receive an email from us with all your membership and login info.

Enjoy all the benefits of our premium membership or you can just buy some of our directories in a PDF on our shop page.

So it's that easy and affordable to join us today for $49 (until the end of 2017 - $99/year starting January 2018)

Don’t miss out on some of the hottest sectors out there….

Thanks and happy trading from the Investorideas.com team !

About Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors. Sectors we cover include tech (AI, drones, internet of things) , payments,  crypto and blockchain, biotech, mining, energy, renewable energy, water , marijuana and hemp stocks, food and beverage, defense and security (biometrics/cyber) ,Latin America, sports, entertainment, luxury brands and gaming.


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411






Friday, December 1, 2017

Investorideas.com - Investor Ideas Adds IPO's in #Biotech, #Tech and #China-#Asia to Directories

Investorideas.com - Investor Ideas Adds IPO's in #Biotech, #Tech and #China-#Asia to Directories



Investorideas.com, a global news source and
investor resource covering actively traded sectors announces this week’s
additions to its
global stock directories in biotech, tech,
China-Asia, mining and AI.



Investorideas.com tracks companies in high-profile
trading sectors and makes ongoing additions to its stock directories for its
members.  Free previews of all
directories are available to the public with full login access only accessible
to members. 

Tuesday, November 28, 2017

Investorideas.com - (CSE: $VRT.C) (OTC: $VRTHF) News: US Patent Office Acknowledges Provisional Patent Application for Use of Specific #Cannabis Strain to Enhance Opioid Analgesia

Investorideas.com - (CSE: $VRT.C) (OTC: $VRTHF) News: US Patent Office Acknowledges Provisional Patent Application for Use of Specific #Cannabis Strain to Enhance Opioid Analgesia



Veritas Pharma Inc. (CSE: VRT; OTC:
VRTHF
;
and Frankfurt: 2VP), (“Veritas” or the “Company”) announces its research arm,
Cannevert Therapeutics Ltd. (“CTL”) filed a provisional patent application to
US Patent and Trademark Office (the “USPTO”) on September 13, 2017 for use of a
specific cannabis strain to enhance the actions of opioid analgesics.  An acknowledgement letter from the USPTO was
received recently which provided a filing number of US 62/558,021 for this
application.

Tuesday, November 21, 2017

Investorideas.com - The Path to New Drug Discoveries and Development with #Cannabis

Investorideas.com - The Path to New Drug Discoveries and Development with #Cannabis



Stocks Mentioned: Veritas Pharma Inc. (CSE: $VRT.C;
OTC: $VRTHF), Zynerba (NASDAQ:  $ZYNE),
GW Pharmaceuticals
(NASDAQ:  $GWPH),
Tetra Bio-Pharma (TSXV:
$TBP.V; $TBPMF), Aphria Inc (TSX: $APH.TO; 
$APHQF)



Point Roberts, WA, November 21, 2017 –
Investorideas.com, a global news source and investor resource covering cannabis
and hemp stocks issues a sector news alert on companies with new drug
discoveries and developments in the sector.

Investorideas.com - #Cannabis Stock News; Veritas' (CSE: $VRT.C) (OTC: $VRTHF) Research Division to Begin Human Trials of Its Lead #Cannabis Strain for Pain; @VeritasPharma

Investorideas.com - #Cannabis Stock News; Veritas' (CSE: $VRT.C) (OTC: $VRTHF) Research Division to Begin Human Trials of Its Lead #Cannabis Strain for Pain; @VeritasPharma



Research
Arm Cannevert Therapeutics Signs LOI with Fundación de Investigación of Puerto
Rico



Vancouver, B.C. - November 21, 2017
(Investorideas.com Newswire) Veritas Pharma Inc.- Cannabis and Biopharma News
alert -  (
CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), ("Veritas" or the
"Company") reports  that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.

Friday, November 17, 2017

Investorideas.com - Investor Ideas Adds $SOGO, $HX, $AQUA, $FNKO, $LOMA, $IFRX, $FEDU $APLS to Directories

Investorideas.com - Investor Ideas Adds $SOGO, $HX, $AQUA, $FNKO, $LOMA, $IFRX, $FEDU $APLS to Directories



Investorideas.com, a global news source and
investor resource covering actively traded sectors announces this week’s
additions to its
global stock directories in tech, biotech,
China-Asia, homebuilder, toy, renewable energy, water, mining & gaming.

Friday, November 10, 2017

Biotech Stocks added; (CSE:CBP), (NasdaqGS:SPRO),(NasdaqGS:ALNA)

Investorideas.com - Investor Ideas Adds #Tech #Stocks: $UBS, $AQ, $ALTR, $ACMR



Investor Ideas Adds #Tech
#Stocks; $UBS, $AQ, $ALTR, $ACMR

Mining Stocks added; (CSE:TUSK), (CSE:SUV),
(TSX:LBY.V),(CSE:DST)

Biotech Stocks added; (CSE:CBP),
(NasdaqGS:SPRO),(NasdaqGS:ALNA) 

Point Roberts, WA, Delta BC – November 10, 2017 –
Investorideas.com, a global news source and investor resource covering actively
traded sectors announces this week’s additions to its
global stock
directories
in tech, mining, biotech & gaming.



Friday, October 13, 2017

#Biotech, #Mining, #Tech, #Energy and #Cannabis #Stocks Added to #Investorideas.com Directories

Investor Ideas Adds #TSX #Mining #Stocks; TSXV: $MTH.V, $MLY.V, $MMA.V, $SME.V, $CCD.V, $AN.V

Biotech, Tech, Energy and Cannabis Stocks Added



Point Roberts, WA, Delta BC – October 13, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its global stock directories in mining, biotech, tech, energy and cannabis.

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listings for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.


The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 14 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas  Stock Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies:http://www.investorideas.com/Investors/Services.asp

Investorideas.com CSE service provider directory listing:http://thecse.com/en/services/services-for-listed-companies

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411

Tuesday, October 10, 2017

Scythian Biosciences Corp.’s (TSXV: $SCYB.V) Professional Athlete Advisory Committee Head, NFL Star Bart Oates says, “Company has a winning team”

Scythian Biosciences Corp.’s (TSXV: $SCYB.V) Professional Athlete Advisory Committee Head, NFL Star Bart Oates says, “Company has a winning team”



October 10, 2017 – Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks issues an exclusive podcast interview with NFL Champion Bart Oates, the first appointment of  the Scythian Biosciences  (TSX.V: SCYB) Professional Athlete Advisory Committee.

Oates, a five-time NFL Pro Bowl player and three-time Super Bowl Champion, was announced as the first appointee to the newly formed committee on October 2. Oates identified the strength of the team in all areas as a guide to why Scythian will be successful.

He also shares his personal experiences with concussions in the NFL and his education of the company’s treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination and how it can make a difference going forward.


Hear the full podcast: 

About Mr. Oates

A former center for the New York Giants and San Francisco 49ers, Bart Oates is a 5-time NFL Pro Bowl player and a 3-time Super Bowl Champion. Once finished with football, Mr. Oates took law classes and then worked as an attorney, receiving his law degree from Seton Hall University. Mr. Oates maintains an active role in many services to the community, including serving as President of the NY/NJ Chapter of the NFL Alumni Association.

Scythian ( http://scythianbio.com/)  is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination. 

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.  The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem.  The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.   

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami.  Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation.  She has extensive experience in neurocognitive testing.  Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995. 

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.


About Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com  is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

The Investorideas.com podcasts are also available on iTunes, Tunein, Stitcher. Spreaker.com, iHeart.com Radio  and Google Play Music.
Visit the Podcast page at Investorideas.com: http://www.investorideas.com/Audio/

Subscribe to Investorideas.com Podcast RSS:

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp


Contact Investorideas.com
800-665-0411

Monday, September 25, 2017

CTO of Scythian Biosciences Corp. (TSXV: $SCYB.V) Talks about Drug Development and Commercialization and Potential of #Cannabinoids

CTO of Scythian Biosciences Corp. (TSXV: $SCYB.V) Talks about Drug Development and Commercialization and Potential of #Cannabinoids

Former VP of Celgene (NASDAQ: $CELG) Talks about Scythian’s Potential Treatment for Concussion and/or TBI

September 25, 2017 – Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks releases an exclusive Q&A  interview with  Maghsoud Dariani, CTO of Scythian Biosciences Corp. (TSXV: SCYB).

Scythian Biosciences Corp. (TSXV: SCYB) reported September 13th that Maghsoud Dariani has become the Chief Scientific Officer of the Company. Mr. Dariani was previously on the Company's advisory board and has over 35 years of experience in the development and commercialization of products in the pharmaceutical industry. Mr. Dariani's experience includes, among other things, management positions at Semorex, Focus Pharmaceuticals, Celgene (NASDAQ: CELG) and Chiral Pharmaceuticals.

Q&A Interview:

Q: Investorideas.com
Congratulations on your recent appointment as Chief Scientific Officer of Scythian Biosciences. Can you talk about your new role and based on the current stage of development of the company’s drug treatment for concussions and traumatic brain injury with its proprietary Cannabinoid combination, what you see as the next steps?

A: Maghsoud Dariani, Chief Scientific Officer
Thank you! I am excited to join Scythian Biosciences and look forward to working with the team to manage the development of our proprietary Cannabinoid combination drug for the treatment of concussion and traumatic brain injury (TBI).  We are extremely fortunate to be collaborating with the University of Miami, a premier research center on concussion and TBI to develop an effective drug treatment for this disorder. TBI, which can result in long-term negative and life altering symptoms affects more than 2 million; mostly young people in the US alone and there is no standard drug treatment, making this a significant unmet need. 

We are currently conducting pre-clinical studies in accepted rodent models to establish the efficacy of our combination drug for TBI and to determine effective dosing.  Upon completion of this stage, we will embark on IND enabling studies, Toxicology, Pharmacokinetics, Pharmacodynamics, ADME (absorption, distribution, metabolism, and excretion), and CMC (chemistry, manufacturing, and control).  We are working with a premier FDA consulting company who will ensure that our pre-clinical and IND enabling studies are in line with FDA requirements and will assist us in preparing our IND package for submission to the FDA.  Upon FDA acceptance of our IND, we will initiate our human clinical trials in collaboration with the University of Miami and possibly other TBI centers of excellence.

Q: Investorideas.com
Can you talk about your 35 years of experience in development and commercialization of products in the pharmaceutical industry?

 A: Maghsoud Dariani, Chief Scientific Officer

Excellent question.  What I have learned during my drug development and commercialization journey is that success requires i) being meticulous and completely thorough during pre-clinical evaluation of drugs under development and ii) paying attention to what the data is telling you during early stages of clinical trials.  Pre-clinical pharmacodynamics is relatively inexpensive and can save a lot of money by preventing the wrong compounds from going forward.  The compounds should be evaluated in as many validated models as possible to ensure both efficacy and safety.  Rushing through this stage and cutting corners can result in costly future failures. Once the compounds have successfully passed through pre-clinical development, careful attention to and thorough analyses of the outcomes from phase I and II clinical trials are critical.  Often, companies and people are under pressure to move compounds to phase III pivotal trials, which are very costly and time consuming.  Failure to do adequate early analyses and ignoring what the data is saying results in disappointing and very costly failures in meeting phase III clinical end points.

Q: Investorideas.com
Do you see  taking a different path or strategy for a smaller  company like Scythian Biosciences  versus  working with a larger company like Celgene Corporation  (NASDAQ: CELG) ?


A: Maghsoud Dariani, Chief Scientific Officer
Fundamentally speaking, NO.  Drug development has distinct stages which have to be followed whether you are a small company or a large one.  The only differences that I see, is that smaller companies are much less bureaucratic and there are a lot less layers.  This simply translates to faster decisions and a somewhat shorter timeline to commercialization.

Q: Investorideas.com
Can you talk about what is unique about the company’s drug (s) in development?

A: Maghsoud Dariani, Chief Scientific Officer

There is currently no approved drug for mild traumatic brain injury and concussion which afflicts more than 2 million mostly young people in the US.  Trauma causes inflammation followed by immune response (gliosis) that can damage nerve cells.  Depending on the severity of the trauma, the resulting symptoms can last for several months or stay with injured people for the rest of their lives. Early and successful drug intervention to reduce inflammation and reduce gliosis is urgently needed.  Our drug under development is a combination of two compounds that attack neuronal inflammation and gliosis through two different pathways.  This is a unique and proprietary approach that has not been tried before.   

Q: Investorideas.com
How do you see Cannabinoids playing a role in the future of pharma and biotech?

A: Maghsoud Dariani, Chief Scientific Officer

The cannabinoid system is present throughout the central nervous system and is crucial for controlling a range neurophysiological processes such as pain, appetite, learning and memory.  The cannabinoid receptors, CB1 and CB2 in the central nervous system are also targets for cannabinoids isolated from the cannabis plant (marijuana) as well as their synthetic analogues. The cannabinoid system has emerged as a key regulator of neuronal cell fate and is seen as capable of conferring neuroprotection.  Many neurological diseases have neurodegenerative components that result from neuroinflammation, oxidative stress and excitotoxicity.  Natural and synthetic cannabinoids represent a class of compounds that are attractive for the development of neurodegenerative diseases such as epilepsy, Tourette’s syndrome, multiple sclerosis, pain, schizophrenia, Alzheimer's disease and cerebral ischemia.

Q: Investorideas.com
In closing on a personal note, what motivated and inspired you to come on board as Chief Scientific Officer of Scythian?

A: Maghsoud Dariani, Chief Scientific Officer

I love challenges and developing a potential treatment for concussion and/or mild traumatic brain injury is a big challenge!  It is a condition with unmet need that afflicts significant number of people.  I also have an excellent track record in overseeing and managing R&D, and when Jonathan asked me to join his team, it was a great fit and I accepted it with enthusiasm.

About Mr. Dariani

Mr. Dariani has over 35 years of diverse and progressive management experience in the development and commercialization of products in the pharmaceutical industry. Mr. Dariani has a successful record of business management, strategic planning, acquisition and divestiture, project management, production management, R&D management, economic evaluations, competitor analyses, and development and administration of multi-million dollar budgets. Mr. Dariani is an entrepreneurial business leader with a sound grasp of successful business strategies, an excellent foundation in science and engineering, and a strong background in product development and commercialization. He is currently the CEO of Semorex Inc. – a privately held company focused on the discovery and development of novel therapeutics for cancer. Mr. Dariani also leads Myos Rens' science and technology efforts and has overall responsibilities for manufacturing, basic science, pre-clinical and clinical studies. Prior to joining Semorex Inc., Mr. Dariani was President of Focus Pharmaceuticals, Inc ("Focus") where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage. Prior to joining Focus, Mr. Dariani was Vice President of the chiral pharmaceutical business unit at Celgene Corporation ("Celgene"). During his twelve years at Celgene, Mr. Dariani developed and implemented Celgene's manufacturing strategy, managed and successfully sold Celgene's chiral intermediates business unit, and formulated a strategic plan for leveraging Celgene's expertise in chiral technologies towards the development of chirally pure drug products. Mr. Dariani was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names. Prior to Celgene, Mr. Dariani held progressively more responsible engineering and development positions at Celanese Corporation. Mr. Dariani holds a Bachelor of Science from The City College of New York and a Master of Science from University of Massachusetts in Chemical Engineering. Mr. Dariani is a member of Board of Directors at Semorex Inc. and Mesa Therapeutics.

Description:
Maghsoud Dariani, Chief Scientific Officer Scythian Biosciences Corp. (TSXV: SCYB)

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

Subscribe to our cannabis news RSS feed: http://www.investorideas.com/rss/feeds/portals/marijuana.xml

For a full list of marijuana and cannabis stocks visit:

About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.   Investorideas.com cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com, The 420 Cannabis Investor ideas www.420cannabisinvestorideas.com and the new AI site  Global Cannabis Investing at www.Globalcannabisinvesting.com.


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured Cannabis Company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Visit the Scythian Biosciences (TSX.V: SCYB) Profile page: http://www.investorideas.com/CO/SCYB/

Contact Investorideas.com

800-665-0411